Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 18 01 2018
accepted: 11 04 2018
pubmed: 28 8 2018
medline: 16 5 2019
entrez: 28 8 2018
Statut: ppublish

Résumé

The aims of this study were to define the risk of serious bacterial infections in patients receiving specific biological disease-modifying anti-rheumatic drugs (bDMARDs) and evaluating the effect of concomitant synthetic DMARDs (sDMARDs) in a large population-based sample of rheumatoid arthritis (RA) deriving from an administrative health database. Data were extracted from health databases of Lombardy Region, Italy (2004-2013), as a part of the RECord-linkage On Rheumatic Diseases (RECORD) study. Patients with RA treated with approved bDMARDs were included. Hospitalisations for bacterial infections were evaluated by hospital discharge forms. The association between drug exposure and infections was assessed by survival models, with time-dependent covariates. Results are presented as hazard ratios (HR) and 95%CI, crude and adjusted for pre-specified confounders (sex, age, disease duration, Charlson Comorbidity Index, previous biologics, previous infections, use of methotrexate, leflunomide, corticosteroids, non-steroidal anti-inflammatory drugs). 4,656 RA patients with at least one bDMARD prescription were included, for a total of 7,601 biological courses; 3,603 (77.4%) women with a mean (SD) age of 55.8 (12.7) years. Crude incidence rate of hospitalised infection ranged from 0.14 to 2.95 per 1000 person-years. After multivariable adjustment, abatacept users (HR 0.29, 95%CI 0.10-0.82) had significantly lower risk of infections compared to etanercept. Concurrent treatment with methotrexate (0.72, 0.52-0.99) reduced the overall risk of infection while glucocorticoids increased it (1.09 per mg/day, 1.06-1.11). In RA patients treated with bDMARDs, abatacept was associated with the lowest risk of infections; overall risk was mitigated by concomitant methotrexate and increased by glucocorticoids in a dose-dependent manner.

Identifiants

pubmed: 30148440
pii: 12628

Substances chimiques

Antirheumatic Agents 0
Biological Products 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

60-66

Auteurs

Greta Carrara (G)

Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.

Alessandra Bortoluzzi (A)

Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.

Garifallia Sakellariou (G)

Chair and Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Italy.

Ettore Silvagni (E)

Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.

Anna Zanetti (A)

Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.

Marcello Govoni (M)

Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.

Carlo Alberto Scirè (CA)

Epidemiology Research Unit, Italian Society for Rheumatology, Milan; and Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy. c.scire@reumatologia.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH